IP Library › Granted Patent US 12,428,497
Granted Patent B2
US 12,428,497 · App. 17/734,253 · Granted Sep 30, 2025

Multispecific antibody constructs

Inventors: Pallavi Bhatta (Slough, GB); Emma Dave (Slough, GB); Sam Philip Heywood (Slough, GB); David Paul Humphreys (Slough, GB)
Assignee: UCB BIOPHARMA SRL
C07K16/468C07K2317/31C07K2317/55C07K2317/622C07K2317/624C07K2317/64C07K2317/94C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,497
App. No.
17/734,253
Granted
Sep 30, 2025
Kind
B2
Abstract

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of a) a polypeptide chain of formula (I): VH—CH 1 —X—V 1 ; and b) a polypeptide chain of formula (II): VL-CL-Y—V 2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

Claims (50)

1. A method of treating a patient in need thereof comprising administering a therapeutically effective amount of a multi-specific antibody molecule comprising

a) a polypeptide chain of formula (I):

V H —CH 1 —X—V 1 ; and

b) a polypeptide chain of formula (II):

V L —C L —Y—V 2 ;

wherein:

V H represents a heavy chain variable domain;

CH 1 represents a domain of a heavy chain constant region;

X represents a bond or linker;

Y represents a bond or linker;

V 1 represents a dsscFv;

V L represents a light chain variable domain;

C L represents a domain from a light chain constant region;

V 2 represents a dsscFv.

2. The method of claim 1 , wherein X is a linker.

3. The method of claim 1 , wherein Y is a linker.

4. The method of claim 1 wherein the light chain variable domain or the heavy chain variable domain of V 1 is attached to X through a peptide bond.

5. The method of claim 1 , wherein the light chain variable domain or the heavy chain variable domain of V 2 is attached to Y through a peptide bond.

6. The method of claim 1 , wherein the heavy chain and light chain variable domains of V1 and/or V2 are linked by a disulfide bond between two cysteine residues, wherein the position of the pair of cysteine residues is selected from the group comprising or consisting of: VH37 and VL95, VH44 and VL100, VH44 and VL105, VH45 and VL87, VH100 and VL50, VH100b and VL49, VH98 and VL46, VH101 and VL46, VH105 and VL43 and VH106 and VL57, wherein the VH and VL values are independently selected within a given V1 or V2, wherein the numbering is according to Kabat.

7. The method of claim 6 , wherein the position of the pair of engineered cysteine residues is VH44 and VL100, wherein the numbering is according to Kabat.

8. The method of claim 1 , wherein X is a peptide linker.

9. The method of claim 1 , wherein Y is a peptide linker.

10. The method of claim 1 , wherein the multi-specific antibody molecule comprises three binding domains and is tri-specific.

11. The method of claim 10 , wherein each of the three binding domains bind different antigens.

12. The method of claim 10 , wherein two binding domains bind the same antigen and the third binding domain binds a second different antigen.

13. The method of claim 1 , wherein V1 and V2 are specific for two different antigens.

14. The method of claim 1 , wherein the multi-specific antibody molecule consists of

a) a polypeptide chain of formula (I):

V H —CH 1 —X—V 1 ; and

b) a polypeptide chain of formula (II):

V L —C L —Y—V 2 ;

wherein:

V H represents a heavy chain variable domain;

CH 1 represents a domain of a heavy chain constant region;

X represents a bond or linker;

Y represents a bond or linker;

V 1 represents a dsscFv;

V L represents a light chain variable domain;

C L represents a domain from a light chain constant region;

V 2 represents a dsscFv; and

wherein V 1 and V 2 are specific for two different antigens.

15. The method of claim 1 , wherein only one of V H /V L , V 1 or V 2 has specificity for a serum carrier protein.

16. The method of claim 15 , wherein the serum carrier protein is human serum albumin and wherein said V H /V L or V 1 or V 2 having specificity for a serum carrier protein forms an albumin binding site.

17. The method of claim 16 , wherein the albumin binding site comprises SEQ ID NO: 71 for CDRH1, SEQ ID NO: 72 for CDRH2, SEQ ID NO: 73 for CDRH3, SEQ ID NO: 74 for CDRL1, SEQ ID NO: 75 for CDRL2 and SEQ ID NO: 76 for CDRL3; or a heavy chain variable domain selected from SEQ ID NO: 77 and SEQ ID NO: 78 and a light chain variable domain selected from SEQ ID NO: 79 and SEQ ID NO: 80.

18. The method of claim 17 , wherein V1 comprises the albumin binding site.

19. The method of claim 17 , wherein V2 comprises the albumin binding site.

20. The method of claim 4 , wherein the heavy chain variable domain of V 1 is attached to X through a peptide bond.

21. The method of claim 5 , wherein the heavy chain variable domain of V 2 is attached to Y through a peptide bond.

22. The method of claim 8 , wherein the peptide linker is selected from the group consisting of SEQ ID NO: 1, 2, 69, and 70.

23. The method of claim 9 , wherein the peptide linker is selected from the group consisting of SEQ ID NO: 1, 2, 69, and 70.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2022
From: BHATTA, PALLAVI; DAVE, EMMA; HEYWOOD, SAM PHILIP; HUMPHREYS, DAVID PAUL
To: UCB BIOPHARMA SPRL
Reel/Frame 059780/0941 →
CHANGE OF NAME Recorded May 2, 2022
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 059843/0179 →
Priority Claims (1)
GB 1411320 · Jun 25, 2014 · national
Continuity (2)
Division 15321055
Related Publication 20220267476A1 · Aug 25, 2022
References Cited (196)
US 4741900A · Alvarez et al. · 1988 [cited by applicant]
US 5219996A · Bodmer et al. · 1993 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5516637A · Huang et al. · 1996 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5658727A · Barbas et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5667425A · Pineau et al. · 1997 [cited by applicant]
US 5698426A · Huse · 1997 [cited by applicant]
US 5733743A · Johnson et al. · 1998 [cited by applicant]
US 5750753A · Kimae et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5780225A · Wigler et al. · 1998 [cited by applicant]
US 5821047A · Garrard et al. · 1998 [cited by applicant]
US 5959083A · Bosslet et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 7138103B2 · Goldenberg et al. · 2006 [cited by applicant]
US 8216805B2 · Carter et al. · 2012 [cited by applicant]
US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]
US 20100081796A1 · Brinkmann et al. · 2010 [cited by applicant]
US 20140120581A1 · Niwa et al. · 2014 [cited by applicant]
EA 15992 · 2012 [cited by applicant]
EP 0392745A2 · 1990 [cited by applicant]
EP 0463151A1 · 1992 [cited by applicant]
EP 546073B1 · 1997 [cited by applicant]
EP 2578230A1 · 2013 [cited by applicant]
EP 2784092A2 · 2014 [cited by applicant]
JP 2004523205A · 2004 [cited by applicant]
JP 2012503612A · 2012 [cited by applicant]
JP 2012503638A · 2012 [cited by applicant]
RU 2473362C2 · 2013 [cited by applicant]
WO WO198601533A1 · 1986 [cited by applicant]
WO WO8900195A1 · 1989 [cited by applicant]
WO WO1989001476A1 · 1989 [cited by applicant]
WO WO199002809A1 · 1990 [cited by applicant]
WO WO9004036A1 · 1990 [cited by applicant]
WO WO9109967A1 · 1991 [cited by applicant]
WO WO9110737A1 · 1991 [cited by applicant]
WO WO9110741A1 · 1991 [cited by applicant]
WO WO9201047A1 · 1992 [cited by applicant]
WO WO92002551A1 · 1992 [cited by applicant]
WO WO9218619A1 · 1992 [cited by applicant]
WO WO9222583A2 · 1992 [cited by applicant]
WO WO9306231A1 · 1993 [cited by applicant]
WO WO9311236A1 · 1993 [cited by applicant]
WO WO9409131A1 · 1994 [cited by applicant]
WO WO9515982A2 · 1995 [cited by applicant]
WO WO9520401A1 · 1995 [cited by applicant]
WO WO9738102A1 · 1997 [cited by applicant]
WO WO1998020734A1 · 1998 [cited by applicant]
WO WO9825971A1 · 1998 [cited by applicant]
WO WO9937791A1 · 1999 [cited by applicant]
WO WO9964460A1 · 1999 [cited by applicant]
WO WO2001030305A1 · 2001 [cited by applicant]
WO WO200177342A1 · 2001 [cited by applicant]
WO WO200190192A2 · 2001 [cited by applicant]
WO WO200208293A2 · 2002 [cited by applicant]
WO WO2003012069A2 · 2003 [cited by applicant]
WO WO03031581A2 · 2003 [cited by applicant]
WO WO04051268A1 · 2004 [cited by applicant]
WO WO04106377A1 · 2004 [cited by applicant]
WO WO05003170A2 · 2005 [cited by applicant]
WO WO2005003169A2 · 2005 [cited by applicant]
WO WO2005003171A2 · 2005 [cited by applicant]
WO WO2005017148A1 · 2005 [cited by applicant]
WO WO05117984A2 · 2005 [cited by applicant]
WO WO2005113605A1 · 2005 [cited by applicant]
WO WO2007095338A2 · 2007 [cited by applicant]
WO WO2007106120A2 · 2007 [cited by applicant]
WO WO2007109254A2 · 2007 [cited by applicant]
WO WO2007146968A2 · 2007 [cited by applicant]
WO WO2008024188A2 · 2008 [cited by applicant]
WO WO2008038024A1 · 2008 [cited by applicant]
WO WO2008094708A2 · 2008 [cited by applicant]
WO WO2009018386A1 · 2009 [cited by applicant]
WO WO2009021754A2 · 2009 [cited by applicant]
WO WO2009023386A2 · 2009 [cited by applicant]
WO WO2009032782A2 · 2009 [cited by applicant]
WO WO2009040562A1 · 2009 [cited by applicant]
WO WO2009068630A1 · 2009 [cited by applicant]
WO WO2010034441A1 · 2010 [cited by applicant]
WO WO2010035012A1 · 2010 [cited by applicant]
WO WO2010112193A1 · 2010 [cited by applicant]
WO WO2010115552A1 · 2010 [cited by applicant]
WO WO2010136172A1 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010145793A1 · 2010 [cited by applicant]
WO WO2011036460A1 · 2011 [cited by applicant]
WO WO2011138391A1 · 2011 [cited by applicant]
WO WO2012025525A1 · 2012 [cited by applicant]
WO WO2012025530A1 · 2012 [cited by applicant]
WO WO2013049234A2 · 2013 [cited by applicant]
WO WO2013068571A1 · 2013 [cited by applicant]
WO WO2013068563A2 · 2013 [cited by applicant]
WO WO2013163427A1 · 2013 [cited by applicant]
WO WO2014096390A1 · 2014 [cited by applicant]
WO WO2014114800A1 · 2014 [cited by applicant]
WO WO2014144722A2 · 2014 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2015181282A1 · 2015 [cited by applicant]
WO WO2016009029A1 · 2016 [cited by applicant]
WO WO2016009030A2 · 2016 [cited by applicant]
WO WO2016170137A1 · 2016 [cited by applicant]
Altschul et al., Basic local alignment search tool. [cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. [cited by applicant]
Ames et al., Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. [cited by applicant]
Babcook et al., A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. [cited by applicant]
Brinkmann et al., A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. [cited by applicant]
Brinkmann et al., Phage display of disulfide-stabilized Fv fragments. [cited by applicant]
Burton et al., Human antibodies from combinatorial libraries. [cited by applicant]
Carter, Bispecific human IgG by design, [cited by applicant]
Chapman, PEGylated antibodies and antibody fragments for improved therapy: a review. [cited by applicant]
Cole et al., The EBV-Hybridoma technique and its application to human lung cancer, [cited by applicant]
Coloma et al., Design and production of novel tetravalent bispecific antibodies. [cited by applicant]
Crameri et al., DNA shuffling of a family of genes from diverse species accelerates directed evolution. [cited by applicant]
Croasdale et al., Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. [cited by applicant]
Dubowchik et al., Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. [cited by applicant]
Fischer et al., Bispecific antibodies: molecules that enable novel therapeutic strategies, [cited by applicant]
Gish et al., Identification of protein coding regions by database similarity search. [cited by applicant]
Glockshuber et al., A comparison of strategies to stabilize immunoglobulin Fv-fragments. [cited by applicant]
Harris, Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture, [cited by applicant]
Holliger et al., Engineered antibody fragments and the rise of single domains, [cited by applicant]
International Preliminary Report on Patentability, PCT/EP2015/064409 (Dec. 27, 2016). [cited by applicant]
International Search Report and Written Opinion, PCT/EP2015/064409 (Sep. 14, 2015). [cited by applicant]
Jung et al., Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. [cited by applicant]
Kabat et al., Sequences of Proteins of Immunological Interest, US Department of Health and Human Services (4th ed. 1983). [cited by applicant]
Kashmiri et al., SDR grafting—a new approach to antibody humanization. [cited by applicant]
Kettleborough et al., Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments. [cited by applicant]
Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. [cited by applicant]
Kontermann, Dual targeting strategies with bispecific antibodies, [cited by applicant]
Kozbor et al., The production of monoclonal antibodies from human lymphocytes. [cited by applicant]
Lanaro et al., Red blood cell survival in patients with Hodgkin's disease. [cited by applicant]
Low et al., Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain, [cited by applicant]
Lu et al., Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments, [cited by applicant]
Luo et al., Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions. [cited by applicant]
Luttgau et al., Immunotherapy of B-Cell lymphoma with an engineered bispecific antibody targeting CD19 and CD5, [cited by applicant]
Madden et al., Applications of network BLAST server. [cited by applicant]
Marks et al., By-passing immunization: building high affinity human antibodies by chain shuffling. [cited by applicant]
Mertens et al., New strategies in polypeptide and antibody synthesis: an overview. [cited by applicant]
Mertens, Empowered Antibodies Congress, Power Point Presentation, Jun. 17-18, 2015, Barcelona. [cited by applicant]
Metz et al., Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing, [cited by applicant]
Orcutt et al., A modular IgG-scFv bispecific antibody topology, [cited by applicant]
Patten et al., Applications of DNA shuffling to pharmaceuticals and vaccines. [cited by applicant]
Persic et al., An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. [cited by applicant]
Rajagopal et al., A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. [cited by applicant]
Riechmann et al., Reshaping human antibodies for therapy, [cited by applicant]
Reiter et al., Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. [cited by applicant]
Reiter et al., Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. [cited by applicant]
Schanzer et al., Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains, [cited by applicant]
Schoonjans et al., A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain, [cited by applicant]
Schoonjans et al., Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. [cited by applicant]
Shen et al., Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies, [cited by applicant]
Spiess et al., Alternative molecular formats and therapeutic applications for bispecific antibodies, [cited by applicant]
Thompson et al., Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactiv… [cited by applicant]
Thorpe et al., The preparation and cytotoxic properties of antibody-toxin conjugates. [cited by applicant]
Vaughan et al., Human antibodies by design. [cited by applicant]
Verma et al., Antibody engineering: Comparision of bacterial yeast, insect and mammalian expression systems, [cited by applicant]
Weatherill et al., Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation, [cited by applicant]
Wells et al., Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites. [cited by applicant]
Yang et al., CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. [cited by applicant]
Young et al., Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. [cited by applicant]
Zhang et al., PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation. [cited by applicant]
Zhu et al., Remodeling domain interfaces to enhance heterodimer formation. [cited by applicant]
Adair et al., Therapeutic Antibodies, Drug Design Reviews. 2:209-17 (2005). [cited by applicant]
Angal et al., A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody, [cited by applicant]
Griffin et al., Computer Analysis of Sequence Data, Part 1, Humana Press, New Jersey, (1994). [cited by applicant]
Hellstrom et al., Antibodies for Drug Delivery, [cited by applicant]
Osol, Remington's Pharmaceutical Sciences, Mack Publishing Company, N.J. (16th ed. 1991). [cited by applicant]
Reiter et al., Antibody Engineering of Recombinant Fv Immunotoxins for Improved Targeting of Cancer: Disulfide-stabilized Fv Immunotoxins. Clinical Cancer Research. 2:245-252 (1996). [cited by applicant]
Webber et al., Preparation and Characterization of a Disulfide-Stabilized Fv Fragment of the Anti-Tac Antibody: Comparison with its Single-Chain Analog. Molecular Immunology. 32: 249-258 (1995). [cited by applicant]
Zhao et al., Stabilization of the Single-Chain Fragment Variable by an Interdomain Disulfide Bond and its Effect on Antibody Affinity. International Journal of Molecular Sciences. 12: 1-11 (2011). [cited by applicant]
Xiang et al., “Recent advances in antibody technique 2. Antibodies of small-molecule and composit function”, Journal of Jinan University (Natoinal Science). 34:556-563 (2013). [cited by applicant]
Lu et al., “Acquired antagonistic activiity of bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2”, Journal of Immunological Methods. 159-171 (1999). [cited by applicant]
Pan et al., “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”, Cancer Cell. 11:53-67 (2007). [cited by applicant]
Comoglio et al., “Drug development of MET inhibitors: targeting oncogene addiction and expedience”, Nature Publishing Group. 7:504-516 (2008). [cited by applicant]
Di Zenzo et al., “The Intracellular and Extracellular DOmains of BP180 Antigen Comprise Novel Epitopes Targeted by Pemphigoid Gestations Autoantibodies”, Journal of Investigative Dermatology. 127: 864-873 (2006). [cited by applicant]
Luo et al. J. Biochem. 118, 825-831, 1995. [cited by applicant]
Roussel et al., Eur. J. Biochem. 260, 192-199,1999. [cited by applicant]
Qu et al. Blood, 111:2211-2218, 2008. [cited by applicant]
Dong et al. (JBC, 2011, vol. 286:4703-4717). [cited by applicant]
Cao et al., (mAbs (2018) 10:8, 1236-1247. [cited by applicant]
Swope et al., “Impact of enzymatic reduction on bivalent bispecific antibody fragmentation and loss of product purity upon reoxidation” (Biotechnology and Bioengineering. 2020; 117:1063-1071. [cited by applicant]
Orcutt et al., (Protein Engineering, Design & Selection, 23:221-228, 2010. [cited by applicant]
Scahnzer et al., (Antimicrobial Agents and Chemotherapy, 55:2369-2378, 2011). [cited by applicant]
Adams et al., (2016) mAbs, 8:7, 1336-1346). [cited by applicant]
Rajagopal et al., Protein Engineering (1997) 10:1453-1459. [cited by applicant]
Reiter et al., “Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments,” Nature Biotechnology, vol. 14, 1239-1245, Oct. 1996. [cited by applicant]
Sheikholvaezin et al. “Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase”, Hybridoma, 25: 181-192, 2006. [cited by applicant]